

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

FINAL PATIENT INFORMATION LEAFLET FOR DAPROHIN

WARNING:

If you are taking DAPROHIN with some medicines used to treat allergies, medicines used to relieve anxiety and/or trouble sleeping, medicines used to correct irregular heartbeat and medicines used to treat migraine headache they may cause serious adverse events.

SCHEDULING STATUS: **S4**

DAPROHIN 400/50 film coated tablets

Darunavir ethanolate and Ritonavir USP

Contains no sugar

Read all of this leaflet carefully before you start taking DAPROHIN

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, pharmacist, nurse or other health care provider.
- DAPROHIN has been prescribed for you personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

What is in this leaflet

1. What DAPROHIN is and what it is used for
2. What you need to know before you take DAPROHIN
3. How to take DAPROHIN
4. Possible side effects
5. How to store DAPROHIN
6. Contents of the pack and other information

1. What DAPROHIN is and what it is used for

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

DAPROHIN contains active substances called darunavir and ritonavir. DAPROHIN is an antiretroviral medicine. It belongs to a group called protease inhibitors. DAPROHIN works by reducing the amount of Human Immunodeficiency Virus (HIV) in your body. This will improve your immune system and reduce the risk of developing illnesses linked to HIV infection.

DAPROHIN is used in combination with other antiretroviral medicines to treat adults who are infected by HIV and who have developed resistance to other antiretroviral medicines.

2. What you need to know before you take DAPROHIN

Do not take DAPROHIN:

- if you are hypersensitive (allergic) to darunavir, ritonavir or any of the other ingredients of DAPROHIN (listed in section 6).
- if you have severe liver disease.

Do not take DAPROHIN with any of the following medicines

- medicines to treat tuberculosis (*rifampicin, rifabutin*)
- medicines to treat high blood pressure as a result of problems with your lungs (*sildenafil, bosentan*)
- medicines to treat migraine and headaches (*dihydroergotamine, ergonovine, ergotamine, methylergonovine*)
- herbal products containing St John's wort (e.g. for depression)
- medicines to treat high cholesterol (*lovastatin and simvastatin*)
- medicines to treat psychiatric conditions such as schizophrenia (*pimozide*)
- medicines to treat trouble with sleeping and/or anxiety (*midazolam or triazolam*)
- medicines to treat fungal infections (*ketoconazole, itraconazole, voriconazole*)
- medicines to treat convulsions (epilepsy) (*phenobarbitone or phenytoin*)
- medicines to treat allergy symptoms (*astemizole*)

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

- medicines to treat gout if you have liver or kidney problems (*colchicine*)
- medicines to treat prostate problems (*alfuzosin*)
- medicines to treat some stomach conditions (*cisapride*)
- medicines to treat hepatitis C virus (*boceprevir, telaprevir*)
- medicines to treat narcotic dependence (*buprenorphine/naloxone*)
- medicines used to correct irregular heart beat (*amiodarone, bepridil, encainide, flecainide, propafenone, quinidine, digoxin*)
- medicines used to treat asthma (*salmeterol*)

If you are taking any of these, discuss it with your doctor.

Warnings and precautions

Take special care with DAPROHIN:

DAPROHIN must be taken together with food. DAPROHIN is not a cure for HIV infection. DAPROHIN does not reduce the risk of passing HIV to others through sexual contact or blood contaminations. Therefore, you must continue to use appropriate precautions, such as condoms.

People taking DAPROHIN may still develop infections or other illnesses associated with HIV infection. You must keep in regular contact with your doctor.

Contact your doctor immediately if the following is experienced:

- severe rash
- sulphonamide (antimicrobial used to treat certain infections) allergy.

Make sure that you check the following points and tell your doctor if any of these apply to you.

- Tell your doctor if you have had **problems with your liver before**. Your doctor may evaluate how severe your liver disease is before deciding if you can take DAPROHIN.
- Tell your doctor if you have **diabetes**. Anti-HIV medicines such as DAPROHIN may increase sugar levels in the blood.

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

- Tell your doctor immediately if you notice any **symptoms of infection**. In some patients with advanced HIV and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
- Tell your doctor if you **notice changes in body fat**. Redistribution, accumulation or loss of body fat may occur in patients receiving a combination of antiretroviral medicines.
- Tell your doctor if you have **haemophilia (bleeding disease)**. Anti-HIV medicines, such as DAPROHIN, may increase the risk of bleeding.
- Tell your doctor if you experience joint aches and pain, joint stiffness or difficulty in movement.
- Tell your doctor if you are allergic to sulpha medicines.
- Some patients taking DAPROHIN can develop serious **problems with their pancreas** (pancreatitis), which may cause death. Tell your doctor as soon as possible if you have nausea, vomiting, or abdominal pain. These may be signs of pancreatitis.
- Blood tests in patients taking DAPROHIN may show possible liver problems. People with liver disease such as **Hepatitis B and Hepatitis C** who take DAPROHIN may have worsening liver disease. Liver problems including rare cases of death have occurred in patients taking DAPROHIN. It is unclear if DAPROHIN caused these liver problems because some patients had other illnesses or were taking other medicines.
- Some patients have large increases in **triglycerides and cholesterol** (fats in the blood).
- **Autoimmune disorders** (a condition that occurs when the immune system attacks healthy body tissue) may also occur after you start taking medicines for the treatment of your HIV infection. Autoimmune disorders may occur many months after the start of treatment. If you notice any symptoms of infection or other symptoms such as muscle weakness, weakness beginning in the hands and feet and moving up towards the trunk of the body, palpitations, tremor or hyperactivity, please inform your doctor immediately to seek necessary treatment.

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

Other medicines and DAPROHIN

Always tell your healthcare professional if you are taking any other medicine. (This includes complementary or traditional medicines.)

There are some medicines that you must not combine with DAPROHIN. These are mentioned above under the heading:

“Do not take DAPROHIN with any of the following medicines”. Tell your doctor if you take any other anti-HIV medicines. DAPROHIN can be combined with some other anti-HIV medicines while other combinations are not recommended.

Tell your doctor if you take:

- medicines to prevent seizures (*carbamazepine*)
- steroids (*dexamethasone*)
- medicines for heart disease or high blood pressure (*amiodarone, bepridil, felodipine, lignocaine, nifedipine, nicardipine, quinidine, digoxin*)
- medicines used to reduce clotting of the blood (*warfarin*)
- oestrogen based hormonal contraceptives. DAPROHIN might reduce the effectiveness of hormonal contraceptives. Therefore, alternative methods of non-hormonal contraception are recommended.
- medicines to lower cholesterol levels (e.g. *atorvastatin, pravastatin and rosuvastatin*). The risk of muscle tissue disorder might be increased. Atorvastatin, pravastatin or rosuvastatin, at a reduced starting dose, could be used.
- medicines for your immune system (*ciclosporin, tacrolimus, sirolimus*). Your doctor might want to do some additional tests.
- medicines to control asthma (*fluticasone and salmeterol*)

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

- medicines for erectile dysfunction (*sildenafil, vardenafil, tadalafil*)
- antibiotics (*clarithromycin*)
- medicines to treat depression and anxiety (*paroxetine, sertraline*)
- medicines to treat narcotic dependence (*methadone*)
- medicines to treat gout or familial Mediterranean fever (*colchicine*)
- a combination medicine to treat malaria (*artemether/lumefantrine*).
- Talk to your doctor if you are taking or are planning to take fluticasone propionate. Taking fluticasone propionate and DAPROHIN can increase the levels of fluticasone in your blood and could cause serious side effects.
- If you are taking rifabutin, your doctor may lower the dose of rifabutin.
- If you are taking both didanosine and DAPROHIN, the dosage times of didanosine and DAPROHIN should be separated by at least 2.5 hours.
- Tell your doctor if you are taking rifampin as it may reduce blood levels of DAPROHIN. (see “Do not take [PRODUCT NAME”])

DAPROHIN with food, drink and alcohol

DAPROHIN must be taken together with food.

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, think you may be pregnant or are planning to become pregnant, please consult your doctor, pharmacist or other health care provider for advice before taking DAPROHIN.

Do not take DAPROHIN during pregnancy and breastfeeding. The safe use of DAPROHIN in pregnancy and during breastfeeding is not known.

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

Studies in animals do not indicate direct harmful effects of darunavir with respect to pregnancy, birth or development after birth.

There is a large information on the use of ritonavir during pregnancy. In general, pregnant mothers received ritonavir after the first three months of pregnancy at a lower dose (booster) along with other protease inhibitors. Ritonavir did not appear to increase the chance of developing birth defects compared to the general population.

Driving and using machines

Sleepiness and dizziness are known undesirable effects of DAPROHIN which may interfere with the ability to perform potentially hazardous tasks like driving a car or operating heavy machinery.

3. How to take DAPROHIN

Do not share medicines prescribed for you with any other person. Always take DAPROHIN exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

The usual dose of DAPROHIN is two tablets once daily. You must take DAPROHIN every day and always in combination with food at approximately the same time of day.

DAPROHIN cannot work properly without food. You must eat a meal or snack 30 minutes before you take your DAPROHIN. The type of food is not important.

Swallow the tablet with a drink such as water, milk, or any other nutritional drink. Even if you feel better, do not stop taking DAPROHIN without talking to your doctor. Make sure that you always have enough DAPROHIN tablets available so that you don't run out. For example, in case you cannot return home, need to travel or stay in a hospital.



Removing the child resistant cap

The plastic bottle comes with a child resistant cap and should be opened as follows:

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

- Push the plastic screw cap down while turning it counterclockwise.
- Remove the unscrewed cap.

If you take more DAPROHIN than you should

In the event of overdosage, consult your doctor or pharmacist. If neither is available, contact the nearest hospital or poison centre.

If you forget to take DAPROHIN

If you notice within 12 hours, you must take your tablet immediately. Always take with food. If you notice after 12 hours, then take the next dose as usual. Do not take a double dose to make up for a forgotten dose.

4. Possible side effects

DAPROHIN can have side effects.

Not all side effects reported for DAPROHIN are included in this leaflet. Should your general health worsen or if you experience any untoward effects while taking DAPROHIN, please consult your doctor, pharmacist or other health care professional for advice.

If any of the following happens, stop taking DAPROHIN and tell your doctor immediately or go to the casualty department of the nearest hospital:

- severe rash with blisters
- rash or itching with swelling of the hands, feet, ankles, face, lips, mouth or throat, which may cause difficulty in swallowing or breathing.

These are all very serious effects. If you have them, you may have had a serious allergic reaction to DAPROHIN. You may need urgent medical attention.

Speak to your doctor immediately or go to the casualty department of your nearest hospital if you experience any of the following side effects:

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

- symptoms of infection or inflammation after the start of treatment (immune reconstitution inflammatory syndrome)
- inflammation of the liver or pancreas (symptoms may include abdominal pain, nausea and vomiting)
- diabetes

These are all serious side effects. You may need urgent medical attention.

Tell your doctor if you notice any of the following:

Frequent side effects:

- headache
- vomiting, nausea
- diarrhoea, stomach pain
- rash
- high cholesterol and other fats in the blood
- high blood sugar
- Weight loss
- Dehydration, increase in cholesterol, gout, swelling of hands and feet
- Agitation, confusion, mood alteration, nervousness
- Tingling sensation or numbness in the hands, feet or around the lips and mouth.
- Bad taste in the mouth; dizziness
- Blurred vision, painful eye, sensitivity to light
- Low blood pressure and feeling faint, when getting up,
- increase in heart beat/rate
- Cough
- Stomach ache, vomiting, diarrhoea, nausea, dry mouth,
- wind, indigestion, mouth ulcer
- Muscular pain
- Joint pain and back pain

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

- Increase/decrease in urination, reduced kidney function
- Feeling weak/tired, fever
- Changes in liver function tests
- Flushing, feeling hot

Less frequent

- Changes in body fats (fat redistribution)
- Loss of appetite
- Abdominal swelling, indigestion, flatulence
- Itching
- Muscle pain
- Loss of strength and energy, tiredness
- Increase in pancreatic enzymes
- Changes in blood test results, Low levels of blood platelets
- High levels of sugar in the blood
- Buzzing/roaring sound in the ear, Pain in the ear,
- Imbalance
- Abnormal dream, difficulty in paying attention, convulsions (fits)
- Change in the heart rate, fainting
- Shortness of breath, nose bleeding
- Decreased sexual drive

DAPROHIN may change some values of your blood chemistry. These can be seen in the results of blood tests. Your doctor will explain these to you. In some patients, DAPROHIN has been reported to cause a severe or life-threatening rash. In patients taking DAPROHIN and raltegravir, rashes (generally mild or moderate) may occur more frequently than in patients taking either medicine separately. Contact your doctor if you develop a rash. Your doctor will advise you whether your symptoms can be managed on therapy or whether DAPROHIN should be

Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd**

Product proprietary name: **DAPROHIN 400/50**

Dosage form and strength: **Film coated tablets and 400 /50 mg**

stopped. DAPROHIN should not be taken if you suffer from liver problems.

If you notice any side effects not mentioned in this leaflet, please Inform your doctor or pharmacist.

Reporting of side effects

If you get side effects, talk to your doctor or pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects to SAHPRA via “**6.04 Adverse Drug Reactions Form**”, found online under SAHPRA’s publications: <https://www.sahpra.org.za/publications/Index/8/>. By reporting side effects, you can help provide more Information on the safety of DAPROHIN.

5 How to store DAPROHIN

Store all medicines out of reach of children

Store at or below 25 °C

Store in the original package

Protect from light/ moisture

Do not use after the expiry date stated on the label

Return all unused medicine to your pharmacist

Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

6. Contents of the pack and other information

What DAPROHIN contains

- The active substances are drunavir ethanolate and ritonavir.
- Silicifide microcrystalline cellulose
- Crospovidone
- Colloidal silicon dioxide
- Magnesium stearate
- Copovidone
- Sorbitan monolaurate

*Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd***

*Product proprietary name: **DAPROHIN 400/50***

*Dosage form and strength: **Film coated tablets and 400 /50 mg***

- Dibasic calcium phosphate anhydrous
- Sodium stearyl fumarate

Composition of Opadry yellow 16C82767

- HPMC/Hypromellose 6cP
- Titanium dioxide
- Macrogol/PEG 400
- HPMC/Hypromellose 15cP
- Hydroxypropyl cellulose
- Iron oxide yellow
- Talc
- Macrogol/PEG 3350
- Colloidal anhydrous silica
- Polysorbate 80

What DAPROHIN looks like and contents of the pack

30's count HDPE container

High density polyethylene container 100 cc with 38 mm Neck (heavy weight) with a child resistant plastic cap with pulp liners 38 mm with a desiccant canister 2,0 g, silica gel

56's and 60's count HDPE container

High density polyethylene container 150 cc with 38 mm Neck (heavy weight) with a child resistant plastic caps with pulp liners 38 mm with a desiccant canister 2,0 g, silica gel

120's count HDPE container

High density polyethylene container 300 cc with 53 mm Neck (heavy weight) with a child resistant plastic cap with pulp liners 53 mm with a desiccant canister 2,0 g, silica gel

*Applicant/PHRC: **Hetero Drugs South Africa (Pty) Ltd***

*Product proprietary name: **DAPROHIN 400/50***

*Dosage form and strength: **Film coated tablets and 400 /50 mg***

Holder of Certificate of Registration

Hetero Drugs South Africa (Pty) Ltd

Waterfall Corporate

Campus, Building No.2,

First Floor, 74 Waterfall Drive, Midrand, 2066

Telephone number: 012 644 1220

Fax number: 012 644 1564

e-mail address: nokuthula.n@heterodrugs.com

This leaflet was last revised in

25 July 2023

Registration number(s)

56/20.2.8/0839.838

Access to the corresponding Professional Information

Hetero Drugs South Africa (Pty) Ltd

Waterfall Corporate

Campus, Building No.2,

First Floor, 74 Waterfall Drive, Midrand, 2066

Telephone number: 012 644 1220

Fax number: 012 644 1564

e-mail address: nokuthula.n@heterodrugs.com